Literature DB >> 12173896

Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model.

N Finnegan1, D Toomey, C Condron, H P Redmond, M Da Costa, D J Bouchier-Hayes.   

Abstract

BACKGROUND: Administration of interleukin-2 (IL-2) is limited by the induction of the vascular leak syndrome (VLS). AIMS: To examine the effect of taurine on the toxicity and antitumour activity of IL-2 in a B16 melanoma pulmonary metastases model.
METHODS: B16 melanoma cells were injected into female C57BL/6 mice. Macroscopic melanoma pulmonary foci were established by day 10 in untreated mice. Treated mice were randomised into treatment by rIL-2 alone, rIL-2 plus taurine or taurine alone. Control animals received saline. Mice were sacrificed on day 18. Lung metastases were counted in a blinded fashion with the aid of a dissecting microscope. Wet to dry lung weight was measured following lung removal. In another experiment animals were treated as above (n = 15 per group) and survival following treatment monitored. RESULT: Treatment with IL-2 and taurine significantly reduced lung nodules compared with IL-2 alone. Host survival was significantly enhanced. The wet to dry (w/d) ratios of lung weights in the group receiving IL-2/taurine were significantly less than IL-2 alone. Bronchoalveolar lavage protein fluid was reduced indicating reduced pulmonary injury.
CONCLUSION: These findings indicate that the combination of taurine with IL-2 augments the efficacy of this immunotherapy while reducing its associated dose-limiting toxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173896     DOI: 10.1007/bf03168959

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  26 in total

1.  Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularization.

Authors:  J Milei; R Ferreira; S Llesuy; P Forcada; J Covarrubias; A Boveris
Journal:  Am Heart J       Date:  1992-02       Impact factor: 4.749

2.  The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases.

Authors:  M L Da Costa; P Redmond; D J Bouchier-Hayes
Journal:  Surgery       Date:  1998-09       Impact factor: 3.982

3.  Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells.

Authors:  D Kotasek; G M Vercellotti; A C Ochoa; F H Bach; J G White; H S Jacob
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

4.  Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).

Authors:  I Nakajima; M Ozaki; H Jinnai; Y Shilayama; T Hirohata; K Okuno; M Yasutomi
Journal:  Cancer Biother       Date:  1993

5.  Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

Authors:  H N Lode; R Xiang; N M Varki; C S Dolman; S D Gillies; R A Reisfeld
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

6.  Successful treatment of murine melanoma with bryostatin 1.

Authors:  L M Schuchter; A H Esa; S May; M K Laulis; G R Pettit; A D Hess
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

7.  An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2.

Authors:  S Fujita; R K Puri; Z X Yu; W D Travis; V J Ferrans
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

8.  Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.

Authors:  R P Whitehead; K D Friedman; D A Clark; K Pagani; L Rapp
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

9.  Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.

Authors:  A Mastino; C Favalli; S Grelli; F Innocenti; E Garaci
Journal:  Cell Immunol       Date:  1991-03       Impact factor: 4.868

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  6 in total

1.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

Review 2.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

3.  Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD).

Authors:  S G Maher; C E M Condron; D J Bouchier-Hayes; D M Toomey
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

4.  Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.

Authors:  G C O'Brien; R A Cahill; D J Bouchier-Hayes; H P Redmond
Journal:  Ir J Med Sci       Date:  2006 Jan-Mar       Impact factor: 1.568

5.  Taurine modulates neutrophil function but potentiates uropathogenic E. coli infection in the murine bladder.

Authors:  Claire Condron; Rowan G Casey; Siobhan Kehoe; Deirdre Toomey; Tom Creagh; David J Bouchier-Hayes
Journal:  Urol Res       Date:  2009-11-26

6.  Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.

Authors:  Ralf Kleef; Ralph Moss; A Marcell Szasz; Arthur Bohdjalian; Hans Bojar; Tibor Bakacs
Journal:  Integr Cancer Ther       Date:  2018-09-07       Impact factor: 3.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.